spacer
home > ict > winter 2017 > smaller world, bigger challenges
PUBLICATIONS
International Clinical Trials

Smaller World, Bigger Challenges

It is the time of year to reflect on 2016’s registration statistics. Unfortunately, the EMA does not publish its annual report until May or June, but the FDA has some interesting information to share (1).

The FDA approved 22 medications in 2016, which was the lowest number in a single year since 2010. In comparison, they authorised 45 news drugs in 2015, with 2014 and 2015 approvals both representing a 19-year high. The EMA compiles its statistics rather differently and the extraction of ‘new’ registrations is something of a challenge. In approximate numbers, the Agency gave approvals to 31 out of a total of 81 new medicines, but these 81 included generics and label extensions. By comparison, there were 40 new molecular entities (NMEs) in 2015 and 46 in 2014. So we may surmise that the engine generating new NMEs is slowing down in spite of continued high investment by pharmaceutical companies. According to consultancy firm Deloitte, returns on R&D investment for the top 12 pharma firms fell to a worrying 3.7% in 2016 from a high of 10.1% in 2010.

Interestingly, only 7 of the 22 NMEs approved by the FDA were small molecules excluding imaging agents, and 12 of the remaining entities were ‘biologicals’ – mainly monoclonal antibodies and nucleotides. Some years ago, the industry thought it was going to generate vast numbers of leads through combinatorial chemistry. This promise has failed to produce the new chemical entities that proceeded to registration.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

Stability Testing and Forced Degradation Stress Tests - Proactive Risk Management

Whereas the durability of many consumables, have a strong tendency to decrease, stability is and remains a crucial factor for pharmaceuticals. That is why the identification and elimination of factors, which put long-term stability at risk, is central during development – and an important requirement concerning the product’s quality.
More info >>

White Papers
 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement